Epitomee Medical Ltd
TASE:EPIT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
255.7
1 503
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Epitomee Medical Ltd
Cost of Revenue
Epitomee Medical Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
Epitomee Medical Ltd
TASE:EPIT
|
Cost of Revenue
-$260k
|
CAGR 3-Years
3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nano-X Imaging Ltd
NASDAQ:NNOX
|
Cost of Revenue
-$16.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Brainsway Ltd
TASE:BWAY
|
Cost of Revenue
-$8.3m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-44%
|
|
|
Inmode Ltd
NASDAQ:INMD
|
Cost of Revenue
-$77.8m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Sisram Medical Ltd
HKEX:1696
|
Cost of Revenue
-$136.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sofwave Medical Ltd
TASE:SOFW
|
Cost of Revenue
-$12.8m
|
CAGR 3-Years
-97%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Epitomee Medical Ltd
Glance View
Epitomee Medical Ltd. develops and manufactures medical devices for obesity. The firm operates directly in the field of development, production and commercialization of medical platforms that are divided into two areas: the area of medical devices for weight loss and overweight, including the development and production of medical devices packed in capsules and ingested; the area of solutions for the introduction of drugs through ingestion that allows patients to take various medications that can be administered today only by injections. Both of the Company's solutions are intended for ingestion for patients for self-use, under a doctor's prescription and are under development.
See Also
What is Epitomee Medical Ltd's Cost of Revenue?
Cost of Revenue
-260k
USD
Based on the financial report for Dec 31, 2023, Epitomee Medical Ltd's Cost of Revenue amounts to -260k USD.
What is Epitomee Medical Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
3%
Over the last year, the Cost of Revenue growth was 29%. The average annual Cost of Revenue growth rates for Epitomee Medical Ltd have been 3% over the past three years .
You don't have any saved screeners yet
